Alpha-1 blockers, which are commonly used in the treatment of benign prostatic hyperplasia (BPH), have shown to be essential in medical expulsive therapy (MET), particularly for distal ureteral calculi. Here, PSMA6 is linked to benign prostatic hyperplasia.